Patents by Inventor Andy J. Minn

Andy J. Minn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunomodulatory RNA
    Publication number: 20230121917
    Abstract: The present invention includes methods for detecting cancer in a subject and measuring the effectiveness of a cancer treatment. In certain embodiments, the invention includes assessing the level of unshielded RN7SL1 RNA in a sample from a subject.
    Type: Application
    Filed: May 19, 2022
    Publication date: April 20, 2023
    Inventors: Andy J. Minn, Barzin Y. Nabet, Lexus R. Johnson
  • Interferon Pathway Genes Regulate and Predict Efficacy of Immunotherapy
    Publication number: 20210269886
    Abstract: The present invention includes methods for treating cancer and selecting a patient for immunotherapy administration.
    Type: Application
    Filed: September 13, 2019
    Publication date: September 2, 2021
    Inventor: Andy J. MINN
  • IMMUNE-ENHANCING RNAS FOR COMBINATION WITH CHIMERIC ANTIGEN RECEPTOR THERAPY
    Publication number: 20200368268
    Abstract: The invention provides compositions and methods for treating diseases such as cancer. The invention also relates to a method of administering a chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
    Type: Application
    Filed: January 8, 2019
    Publication date: November 26, 2020
    Inventors: Lexus R. Johnson, Carl H. June, Andy J. Minn
  • IMMUNOMODULATORY RNA
    Publication number: 20180298450
    Abstract: The present invention includes methods for detecting cancer in a subject and measuring the effectiveness of a cancer treatment. In certain embodiments, the invention includes assessing the level of unshielded RN7SL1 RNA in a sample from a subject.
    Type: Application
    Filed: April 6, 2018
    Publication date: October 18, 2018
    Inventors: Andy J. MINN, Barzin Y. NABET
  • Method of predicting and reducing risk of metastasis of breast cancer to lung
    Patent number: 8906606
    Abstract: A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: December 9, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gaorav P. Gupta, Joan Massague, Andy J. Minn
  • Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung
    Publication number: 20120294872
    Abstract: A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations.
    Type: Application
    Filed: April 16, 2012
    Publication date: November 22, 2012
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Gaorav P. Gupta, Joan Massague, Andy J. Minn